[Click eStock] "Samsung Biologics, Strong Contract Manufacturing Demand... Target Price Up"

On the 12th, iM Securities maintained a 'Buy' rating on Samsung Biologics, citing steady demand for large-scale antibody contract manufacturing. The target price was raised from 1,050,000 KRW to 1,150,000 KRW.

Jang Min-hwan, a researcher at iM Securities, stated, "As the outsourcing trend of client companies continues, the strategy of focusing on commercial production of antibody drugs will remain effective in the short to medium term," adding, "Through proactive capacity expansion, production capacity of 784,000 liters will be secured by April next year, enabling rapid ramp-up based on high demand for mass production."

Researcher Jang also noted, "There are not many global contract development and manufacturing organizations (CDMOs) capable of handling the demand for blockbuster drugs worldwide," and forecasted, "The risks faced by competitors, highlighted by the Biosecurity Act, will benefit Samsung Biologics." He further added, "Building meaningful factors such as securing payload platform technology and facilities for producing high-potency active pharmaceutical ingredients (HPAPI) in the future could enhance corporate value."

This content was produced with the assistance of AI translation services.